2,785 results match your criteria Breast Cancer Research[Journal]


Airborne metals and polycyclic aromatic hydrocarbons in relation to mammographic breast density.

Breast Cancer Res 2019 Feb 13;21(1):24. Epub 2019 Feb 13.

Departments of Surgery and Radiology, University of Vermont, Burlington, VT, USA.

Background: Breast density is strongly related to breast cancer. Identifying associations between environmental exposures and density may elucidate relationships with breast cancer. Metals and polycyclic aromatic hydrocarbons (PAHs) may influence breast density via oxidative stress or endocrine disruption. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s13058-019-1110-7DOI Listing
February 2019

CXCL17-derived CD11bGr-1 myeloid-derived suppressor cells contribute to lung metastasis of breast cancer through platelet-derived growth factor-BB.

Breast Cancer Res 2019 Feb 12;21(1):23. Epub 2019 Feb 12.

Center for Biomarkers and Biotech Drugs, Kaohsiung Medical University, Kaohsiung, 807, Taiwan.

Background: Metastasis is the major cause of death from breast cancer. Colonization and adaption of metastatic cells in distant organs is a rate-limiting step of the cancer spreading. The underlying mechanisms responsible for the colonization of breast cancer to lung metastatic niches are not fully understood. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s13058-019-1114-3DOI Listing
February 2019

Targeted mutation detection in breast cancer using MammaSeq™.

Breast Cancer Res 2019 Feb 8;21(1):22. Epub 2019 Feb 8.

Department of Pharmacology and Chemical Biology, and Human Genetics, UPMC Hillman Cancer Center, Magee-Womens Research Institute, University of Pittsburgh, 204 Craft Avenue, Pittsburgh, PA, 15213, USA.

Background: Breast cancer is the most common invasive cancer among women worldwide. Next-generation sequencing (NGS) has revolutionized the study of cancer across research labs around the globe; however, genomic testing in clinical settings remains limited. Advances in sequencing reliability, pipeline analysis, accumulation of relevant data, and the reduction of costs are rapidly increasing the feasibility of NGS-based clinical decision making. Read More

View Article

Download full-text PDF

Source
https://breast-cancer-research.biomedcentral.com/articles/10
Publisher Site
http://dx.doi.org/10.1186/s13058-019-1102-7DOI Listing
February 2019
1 Read

Exosomal miRNA profile as complementary tool in the diagnostic and prediction of treatment response in localized breast cancer under neoadjuvant chemotherapy.

Breast Cancer Res 2019 Feb 6;21(1):21. Epub 2019 Feb 6.

Liquid biopsy and metastasis research group, GENYO, Centre for Genomics and Oncological Research, Pfizer/University of Granada/Andalusian Regional Government PTS, Granada, Avenida de la Ilustración 114, 18016, Granada, Spain.

Background: Breast cancer patients under neoadjuvant chemotherapy includes a heterogeneous group of patients who eventually develop distal disease, not detectable by current methods. We propose the use of exosomal miRNAs and circulating tumor cells as diagnostic and predictive biomarkers in these patients.

Methods: Fifty-three breast cancer women initially diagnosed with localized breast cancer under neoadjuvant chemotherapy were prospectively enrolled in this study. Read More

View Article

Download full-text PDF

Source
https://breast-cancer-research.biomedcentral.com/articles/10
Publisher Site
http://dx.doi.org/10.1186/s13058-019-1109-0DOI Listing
February 2019
2 Reads

MiR-1287-5p inhibits triple negative breast cancer growth by interaction with phosphoinositide 3-kinase CB, thereby sensitizing cells for PI3Kinase inhibitors.

Breast Cancer Res 2019 Feb 1;21(1):20. Epub 2019 Feb 1.

Division of Oncology, Department of Internal Medicine, Medical University of Graz (MUG), Graz, Austria.

Background: Non-coding RNAs and especially microRNAs have been discovered to act as master regulators of cancer initiation and progression. The aim of our study was to discover and characterize the function of yet functionally uncharacterized microRNAs in human breast carcinogenesis.

Methods: In an unbiased approach, we utilized an established model system for breast cancer (BC) stem cell formation ("mammosphere assay") to identify whole miRNome alterations in breast carcinogenesis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s13058-019-1104-5DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6359814PMC
February 2019

A subgroup of microRNAs defines PTEN-deficient, triple-negative breast cancer patients with poorest prognosis and alterations in RB1, MYC, and Wnt signaling.

Breast Cancer Res 2019 Jan 31;21(1):18. Epub 2019 Jan 31.

Toronto General Research Institute - University Health Network, 67 College Street, Rm. 407, Toronto, Ontario, M5G 2M1, Canada.

Background: Triple-negative breast cancer (TNBC) represents a heterogeneous group of ER- and HER2-negative tumors with poor clinical outcome. We recently reported that Pten-loss cooperates with low expression of microRNA-145 to induce aggressive TNBC-like lesions in mice. To systematically identify microRNAs that cooperate with PTEN-loss to induce aggressive human BC, we screened for miRNAs whose expression correlated with PTEN mRNA levels and determined the prognostic power of each PTEN-miRNA pair alone and in combination with other miRs. Read More

View Article

Download full-text PDF

Source
https://breast-cancer-research.biomedcentral.com/articles/10
Publisher Site
http://dx.doi.org/10.1186/s13058-019-1098-zDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6357448PMC
January 2019
2 Reads

Radiologic complete response (rCR) in contrast-enhanced magnetic resonance imaging (CE-MRI) after neoadjuvant chemotherapy for early breast cancer predicts recurrence-free survival but not pathologic complete response (pCR).

Breast Cancer Res 2019 Jan 31;21(1):19. Epub 2019 Jan 31.

Department of Internal Medicine III with Hematology, Medical Oncology, Hemostaseology, Infectiology and Rheumatology, Oncologic Center; Salzburg Cancer Research Institute - Laboratory for Immunological and Molecular Cancer Research (SCRI-LIMCR), Paracelsus Medical University, Salzburg, Austria.

Background: Patients with early breast cancer (EBC) achieving pathologic complete response (pCR) after neoadjuvant chemotherapy (NACT) have a favorable prognosis. Breast surgery might be avoided in patients in whom the presence of residual tumor can be ruled out with high confidence. Here, we investigated the diagnostic accuracy of contrast-enhanced MRI (CE-MRI) in predicting pCR and long-term outcome after NACT. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s13058-018-1091-yDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6357474PMC
January 2019

Serum erythropoietin levels, breast cancer and breast cancer-initiating cells.

Breast Cancer Res 2019 Jan 30;21(1):17. Epub 2019 Jan 30.

Department of Radiation Oncology, David Geffen School of Medicine at UCLA, 10833 Le Conte Ave, Los Angeles, CA, 90095-1714, USA.

Background: Cancer is frequently associated with tumor-related anemia, and many chemotherapeutic agents impair hematopoiesis, leading to impaired quality of life for affected patients. The use of erythropoiesis-stimulating agents has come under scrutiny after prospective clinical trials using recombinant erythropoietin to correct anemia reported increased incidence of thromboembolic events and cancer-related deaths. Furthermore, previous preclinical reports indicated expansion of the pool of breast cancer-initiating cells when erythropoietin was combined with ionizing radiation. Read More

View Article

Download full-text PDF

Source
https://breast-cancer-research.biomedcentral.com/articles/10
Publisher Site
http://dx.doi.org/10.1186/s13058-019-1100-9DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6354373PMC
January 2019
2 Reads

Associations between dietary patterns and the risk of breast cancer: a systematic review and meta-analysis of observational studies.

Breast Cancer Res 2019 Jan 29;21(1):16. Epub 2019 Jan 29.

MPH Education Center, Shantou University Medical College, Shantou, Guangdong, China.

Background: Epidemiologic evidence suggests that certain dietary patterns were associated with breast cancer risk, but the results have been inconclusive. We assessed the associations between different dietary patterns and the risk of breast cancer by conducting a meta-analysis of observational studies.

Methods: Relevant articles were searched in PubMed, Embase, and Cochrane library databases through September 2017. Read More

View Article

Download full-text PDF

Source
https://breast-cancer-research.biomedcentral.com/articles/10
Publisher Site
http://dx.doi.org/10.1186/s13058-019-1096-1DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6352362PMC
January 2019
1 Read

Molecular and epigenetic profiles of BRCA1-like hormone-receptor-positive breast tumors identified with development and application of a copy-number-based classifier.

Breast Cancer Res 2019 Jan 25;21(1):14. Epub 2019 Jan 25.

Department of Epidemiology, Lebanon, USA.

Background: BRCA1-mutated cancers exhibit deficient homologous recombination (HR) DNA repair, resulting in extensive copy number alterations and genome instability. HR deficiency can also arise in tumors without a BRCA1 mutation. Compared with other breast tumors, HR-deficient, BRCA1-like tumors exhibit worse prognosis but selective chemotherapeutic sensitivity. Read More

View Article

Download full-text PDF

Source
https://breast-cancer-research.biomedcentral.com/articles/10
Publisher Site
http://dx.doi.org/10.1186/s13058-018-1090-zDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6347811PMC
January 2019
2 Reads

p53 controls the plasticity of mammary luminal progenitor cells downstream of Met signaling.

Breast Cancer Res 2019 Jan 25;21(1):13. Epub 2019 Jan 25.

Institut Curie, PSL Research University, CNRS, UMR144, 26 rue d'Ulm, F-75005, Paris, France.

Background: The adult mammary epithelium is composed of basal and luminal cells. The luminal lineage comprises two major cell populations, positive and negative for estrogen and progesterone receptors (ER and PR, respectively), both containing clonogenic progenitor cells. Deregulated ER/PR luminal progenitor cells are suspected to be at the origin of basal-type triple-negative (TNBC) breast cancers, a subtype frequently associated with loss of P53 function and MET signaling hyperactivation. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s13058-019-1101-8DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6346556PMC
January 2019
10 Reads

Intravital imaging reveals systemic ezrin inhibition impedes cancer cell migration and lymph node metastasis in breast cancer.

Breast Cancer Res 2019 Jan 24;21(1):12. Epub 2019 Jan 24.

Department of Pathology and Molecular Medicine, Queen's University, Kingston, Canada.

Background: Limited understanding of the cancer biology of metastatic sites is a major factor contributing to poor outcomes in cancer patients. The regional lymph nodes are the most common site of metastasis in most solid cancers and their involvement is a strong predictor of relapse in breast cancer (BC). We have previously shown that ezrin, a cytoskeletal-membrane linker protein, is associated with lymphovascular invasion and promotes metastatic progression in BC. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s13058-018-1079-7DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6345049PMC
January 2019

Methylglyoxal, a glycolysis metabolite, triggers metastasis through MEK/ERK/SMAD1 pathway activation in breast cancer.

Breast Cancer Res 2019 Jan 23;21(1):11. Epub 2019 Jan 23.

Metastasis Research Laboratory, GIGA-Cancer, University of Liège (ULiège), Pathology Tour, +4 level, Building 23, Avenue Hippocrate 13, 4000, Liège, Belgium.

Background: Elevated aerobic glycolysis rate is a biochemical alteration associated with malignant transformation and cancer progression. This metabolic shift unavoidably generates methylglyoxal (MG), a potent inducer of dicarbonyl stress through the formation of advanced glycation end products (AGEs). We have previously shown that the silencing of glyoxalase 1 (GLO1), the main MG detoxifying enzyme, generates endogenous dicarbonyl stress resulting in enhanced growth and metastasis in vivo. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s13058-018-1095-7DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6343302PMC
January 2019

Localized mammographic density is associated with interval cancer and large breast cancer: a nested case-control study.

Breast Cancer Res 2019 Jan 22;21(1). Epub 2019 Jan 22.

Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Nobels Väg 12A, 171 77, Stockholm, Sweden.

Background: High mammographic density is associated with breast cancer and with delayed detection. We have examined whether localized density, at the site of the subsequent cancer, is independently associated with being diagnosed with a large-sized or interval breast cancer.

Methods: Within a prospective cohort of 63,130 women, we examined 891 women who were diagnosed with incident breast cancer. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s13058-019-1099-yDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6341532PMC
January 2019

Combining the oncolytic peptide LTX-315 with doxorubicin demonstrates therapeutic potential in a triple-negative breast cancer model.

Breast Cancer Res 2019 Jan 22;21(1). Epub 2019 Jan 22.

Department of Tumor Biology, Institute for Cancer Research, Oslo University Hospital, NO-0379, Oslo, Norway.

Background: Immunochemotherapy, the combined use of immunotherapy and chemotherapy, has demonstrated great promise in several cancers. LTX-315 is an oncolytic peptide with potent immunomodulatory properties designed for the local treatment of solid tumors. By inducing rapid immunogenic cell death through the release of danger-associated molecular pattern molecules (DAMPs), LTX-315 is capable of reshaping the tumor microenvironment, turning "cold" tumors "hot" through a significant increase in tumor-infiltrating lymphocytes. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s13058-018-1092-xDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6343247PMC
January 2019

HER2 regulates HIF-2α and drives an increased hypoxic response in breast cancer.

Breast Cancer Res 2019 Jan 22;21(1):10. Epub 2019 Jan 22.

Cancer Research UK Edinburgh Centre and Division of Pathology Laboratory, Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh, EH4 2XU, UK.

Background: Tumour hypoxia is a driver of breast cancer progression associated with worse prognosis and more aggressive disease. The cellular response to hypoxia is mediated by the hypoxia-inducible transcription factors HIF-1 and HIF-2, whose transcriptional activity is canonically regulated through their oxygen-labile HIF-α subunits. These are constitutively degraded in the presence of oxygen; however, HIF-1α can be stabilised, even at high oxygen concentrations, through the activation of HER receptor signalling. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s13058-019-1097-0DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6343358PMC
January 2019

Adipocytes promote breast cancer resistance to chemotherapy, a process amplified by obesity: role of the major vault protein (MVP).

Breast Cancer Res 2019 Jan 17;21(1). Epub 2019 Jan 17.

Institut de Pharmacologie et de Biologie Structurale (IPBS), Université de Toulouse, CNRS, UPS, UMR 5089, 205 route de Narbonne, 31077, Toulouse, France.

Introduction: Clinical studies suggest that obesity, in addition to promoting breast cancer aggressiveness, is associated with a decrease in chemotherapy efficacy, although the mechanisms involved remain elusive. As chemotherapy is one of the main treatments for aggressive or metastatic breast cancer, we investigated whether adipocytes can mediate resistance to doxorubicin (DOX), one of the main drugs used to treat breast cancer, and the mechanisms associated.

Methods: We used a coculture system to grow breast cancer cells with in vitro differentiated adipocytes as well as primary mammary adipocytes isolated from lean and obese patients. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s13058-018-1088-6DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6337862PMC
January 2019
1 Read

Hydrodynamic shear stress promotes epithelial-mesenchymal transition by downregulating ERK and GSK3β activities.

Breast Cancer Res 2019 Jan 16;21(1). Epub 2019 Jan 16.

Department of Stem Cell & Regenerative Biotechnology and Incurable Disease Animal Model and Stem Cell Institute (IDASI), Konkuk University, 120 Neungdong-ro, Gwangjin-gu, Seoul, 05029, Republic of Korea.

Background: Epithelial-mesenchymal transition (EMT) occurs in the tumor microenvironment and presents an important mechanism of tumor cell intravasation, stemness acquisition, and metastasis. During metastasis, tumor cells enter the circulation to gain access to distant tissues, but how this fluid microenvironment influences cancer cell biology is poorly understood.

Methods And Results: Here, we present both in vivo and in vitro evidence that EMT-like transition also occurs in circulating tumor cells (CTCs) as a result of hydrodynamic shear stress (+SS), which promotes conversion of CD24/CD44/CD133/CXCR4/ALDH1 primary patient epithelial tumor cells into specific high sphere-forming CD24/CD44/CD133/CXCR4/ALDH1 cancer stem-like cells (CSLCs) or tumor-initiating cells (TICs) with elevated tumor progression and metastasis capacity in vitro and in vivo. Read More

View Article

Download full-text PDF

Source
https://breast-cancer-research.biomedcentral.com/articles/10
Publisher Site
http://dx.doi.org/10.1186/s13058-018-1071-2DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6335853PMC
January 2019
3 Reads

Using an in-vivo syngeneic spontaneous metastasis model identifies ID2 as a promoter of breast cancer colonisation in the brain.

Breast Cancer Res 2019 Jan 14;21(1). Epub 2019 Jan 14.

The Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, 237 Fulham Road, London, SW3 6JB, UK.

Background: Dissemination of breast cancers to the brain is associated with poor patient outcome and limited therapeutic options. In this study we sought to identify novel regulators of brain metastasis by profiling mouse mammary carcinoma cells spontaneously metastasising from the primary tumour in an immunocompetent syngeneic host.

Methods: 4T1 mouse mammary carcinoma sublines derived from primary tumours and spontaneous brain and lung metastases in BALB/c mice were subject to genome-wide expression profiling. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s13058-018-1093-9DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6332688PMC
January 2019
3 Reads

Identification of novel common breast cancer risk variants at the 6q25 locus among Latinas.

Breast Cancer Res 2019 Jan 14;21(1). Epub 2019 Jan 14.

Division of General Internal Medicine, Department of Medicine, Institute of Human Genetics, Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, Box 0320, San Francisco, CA, 94143, USA.

Background: Breast cancer is a partially heritable trait and genome-wide association studies (GWAS) have identified over 180 common genetic variants associated with breast cancer. We have previously performed breast cancer GWAS in Latinas and identified a strongly protective single nucleotide polymorphism (SNP) at 6q25, with the protective minor allele originating from indigenous American ancestry. Here we report on fine mapping of the 6q25 locus in an expanded sample of Latinas. Read More

View Article

Download full-text PDF

Source
https://breast-cancer-research.biomedcentral.com/articles/10
Publisher Site
http://dx.doi.org/10.1186/s13058-018-1085-9DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6332913PMC
January 2019
6 Reads

Context-dependent roles of MDMX (MDM4) and MDM2 in breast cancer proliferation and circulating tumor cells.

Breast Cancer Res 2019 Jan 14;21(1). Epub 2019 Jan 14.

Graduate Center Biology Program, Hunter College, City University of New York, Belfer Building, New York, NY, USA.

Introduction: Many human breast cancers overexpress the E3 ubiquitin ligase MDM2 and its homolog MDMX. Expression of MDM2 and MDMX occurs in estrogen receptor α-positive (ERα) breast cancer and triple-negative breast cancer (TNBC). There are p53-independent influences of MDM2 and MDMX, and 80% of TNBC express mutant p53 (mtp53). Read More

View Article

Download full-text PDF

Source
https://breast-cancer-research.biomedcentral.com/articles/10
Publisher Site
http://dx.doi.org/10.1186/s13058-018-1094-8DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6332579PMC
January 2019
6 Reads

Molecular changes during extended neoadjuvant letrozole treatment of breast cancer: distinguishing acquired resistance from dormant tumours.

Breast Cancer Res 2019 Jan 7;21(1). Epub 2019 Jan 7.

Applied Bioinformatics of Cancer, University of Edinburgh Cancer Research UK Centre, MRC Institute of Genetics and Molecular Medicine, Edinburgh, UK.

Background: The risk of recurrence for endocrine-treated breast cancer patients persists for many years or even decades following surgery and apparently successful adjuvant therapy. This period of dormancy and acquired resistance is inherently difficult to investigate; previous efforts have been limited to in-vitro or in-vivo approaches. In this study, sequential tumour samples from patients receiving extended neoadjuvant aromatase inhibitor therapy were characterised as a novel clinical model. Read More

View Article

Download full-text PDF

Source
https://breast-cancer-research.biomedcentral.com/articles/10
Publisher Site
http://dx.doi.org/10.1186/s13058-018-1089-5DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6323855PMC
January 2019
7 Reads

A method of producing genetically manipulated mouse mammary gland.

Breast Cancer Res 2019 Jan 5;21(1). Epub 2019 Jan 5.

Department of Life Science and Medical Bioscience, School of Advanced Science and Engineering, Waseda University, 2-2 Wakamatsu-cho, Shinjuku-ku, Tokyo, 162-8480, Japan.

Background: To obtain a deep understanding of the mechanism by which breast cancer develops, the genes involved in tumorigenesis should be analyzed in vivo. Mouse mammary gland can regenerate completely from a mammary stem cell (MaSC), which enables us to analyze the effect of gene expression and repression on tumorigenesis in mammary gland regenerated from genetically manipulated MaSCs. Although lentiviral and retroviral systems have usually been applied for gene transduction into MaSCs, they are associated with difficulty in introducing long, repeated, or transcriptional termination sequences. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s13058-018-1086-8DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6321679PMC
January 2019
2 Reads

Adjusting for BMI in analyses of volumetric mammographic density and breast cancer risk.

Breast Cancer Res 2018 12 29;20(1):156. Epub 2018 Dec 29.

Faculty of Population Health Sciences, Institute of Child Health, University College London, London, WC1N 1EH, UK.

Background: Fully automated assessment of mammographic density (MD), a biomarker of breast cancer risk, is being increasingly performed in screening settings. However, data on body mass index (BMI), a confounder of the MD-risk association, are not routinely collected at screening. We investigated whether the amount of fat in the breast, as captured by the amount of mammographic non-dense tissue seen on the mammographic image, can be used as a proxy for BMI when data on the latter are unavailable. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s13058-018-1078-8DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6311032PMC
December 2018
2 Reads

Prospective validation of the NCI Breast Cancer Risk Assessment Tool (Gail Model) on 40,000 Australian women.

Breast Cancer Res 2018 12 20;20(1):155. Epub 2018 Dec 20.

Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Victoria, 3000, Australia.

Background: There is a growing interest in delivering more personalised, risk-based breast cancer screening protocols. This requires population-level validation of practical models that can stratify women into breast cancer risk groups. Few studies have evaluated the Gail model (NCI Breast Cancer Risk Assessment Tool) in a population screening setting; we validated this tool in a large, screened population. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s13058-018-1084-xDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6302513PMC
December 2018
1 Read

Overdiagnosis in the population-based organized breast cancer screening program estimated by a non-homogeneous multi-state model: a cohort study using individual data with long-term follow-up.

Breast Cancer Res 2018 12 17;20(1):153. Epub 2018 Dec 17.

Department of Radiation Sciences, Oncology, Umeå University, 90187, Umeå, Sweden.

Background: Overdiagnosis, defined as the detection of a cancer that would not become clinically apparent in a woman's lifetime without screening, has become a growing concern. Similar underlying risk of breast cancer in the screened and control groups is a prerequisite for unbiased estimates of overdiagnosis, but a contemporary control group is usually not available in organized screening programs.

Methods: We estimated the frequency of overdiagnosis of breast cancer due to screening in women 50-69 years old by using individual screening data from the population-based organized screening program in Stockholm County 1989-2014. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s13058-018-1082-zDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6296133PMC
December 2018
1 Read

CD68, CD163, and matrix metalloproteinase 9 (MMP-9) co-localization in breast tumor microenvironment predicts survival differently in ER-positive and -negative cancers.

Breast Cancer Res 2018 12 17;20(1):154. Epub 2018 Dec 17.

Department of Pathology, Yale School of Medicine, 310 Cedar Street, P.O. Box 208023, New Haven, CT, 06520, USA.

Background: The role of tumor-associated macrophages (TAMs) in the cancer immune landscape and their potential as treatment targets or modulators of response to treatment are gaining increasing interest. TAMs display high molecular and functional complexity. Therefore their objective assessment as breast cancer biomarkers is critical. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s13058-018-1076-xDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6298021PMC
December 2018
1 Read

Predicting interval and screen-detected breast cancers from mammographic density defined by different brightness thresholds.

Breast Cancer Res 2018 12 13;20(1):152. Epub 2018 Dec 13.

Centre for Epidemiology and Biostatistics, The University of Melbourne, Level 3/207 Bouverie Street, Carlton, VIC, 3053, Australia.

Background: Case-control studies show that mammographic density is a better risk factor when defined at higher than conventional pixel-brightness thresholds. We asked if this applied to interval and/or screen-detected cancers.

Method: We conducted a nested case-control study within the prospective Melbourne Collaborative Cohort Study including 168 women with interval and 422 with screen-detected breast cancers, and 498 and 1197 matched controls, respectively. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s13058-018-1081-0DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6293866PMC
December 2018
1 Read

ErbB2-driven downregulation of the transcription factor Irf6 in breast epithelial cells is required for their 3D growth.

Breast Cancer Res 2018 12 13;20(1):151. Epub 2018 Dec 13.

Department of Pediatrics, Dalhousie University, Halifax, NS, Canada.

Background: The ability of solid tumor cells to resist anoikis, apoptosis triggered by cell detachment from the extracellular matrix (ECM), is thought to be critical for 3D tumor growth. ErbB2/Her2 oncoprotein is often overproduced by breast tumor cells and blocks their anoikis by partially understood mechanisms. In our effort to understand them better, we observed that detachment of nonmalignant human breast epithelial cells from the ECM upregulates the transcription factor Irf6. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s13058-018-1080-1DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6293553PMC
December 2018
3 Reads

The isomiR-140-3p-regulated mevalonic acid pathway as a potential target for prevention of triple negative breast cancer.

Breast Cancer Res 2018 12 11;20(1):150. Epub 2018 Dec 11.

Department of Breast Surgical Oncology, The University of Texas MD Anderson Cancer, 1515 Holcombe Blvd, Houston, TX, 77030, USA.

Background: Prevention of triple-negative breast cancer (TNBC) is hampered by lack of knowledge about the drivers of tumorigenesis.

Methods: To identify molecular markers and their downstream networks that can potentially be targeted for TNBC prevention, we analyzed small RNA and RNA sequencing of a cell line model that represent early stages of TNBC development. We have identified direct gene targets of isomiRNA-140-3p and by using cell-based and in vivo model systems we have demonstrated the utility of targeting downstream pathways for prevention of TNBC. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s13058-018-1074-zDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6290546PMC
December 2018
1 Read

CYP2D6 phenotype, tamoxifen, and risk of contralateral breast cancer in the WECARE Study.

Breast Cancer Res 2018 12 10;20(1):149. Epub 2018 Dec 10.

Memorial Sloan Kettering Cancer Center, New York, NY, USA.

Background: Tamoxifen treatment greatly reduces a woman's risk of developing a second primary breast cancer. There is, however, substantial variability in treatment response, some of which may be attributed to germline genetic variation. CYP2D6 is a key enzyme in the metabolism of tamoxifen to its active metabolites, and variants in this gene have been associated with reduced tamoxifen metabolism. Read More

View Article

Download full-text PDF

Source
https://breast-cancer-research.biomedcentral.com/articles/10
Publisher Site
http://dx.doi.org/10.1186/s13058-018-1083-yDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6288916PMC
December 2018
10 Reads

Alterations in arginine and energy metabolism, structural and signalling lipids in metastatic breast cancer in mice detected in plasma by targeted metabolomics and lipidomics.

Breast Cancer Res 2018 12 4;20(1):148. Epub 2018 Dec 4.

Jagiellonian University, Jagiellonian Centre for Experimental Therapeutics, Bobrzynskiego 14, 30-348, Krakow, Poland.

Background: The early detection of metastasis based on biomarkers in plasma may improve cancer prognosis and guide treatment. The aim of this work was to characterize alterations in metabolites of the arginine pathway, energy metabolism, and structural and signalling lipids in plasma in the early and late stages of murine breast cancer metastasis.

Methods: Mice were orthotopically inoculated with 4T1 metastatic breast cancer cells, and plasma was analysed along the pulmonary metastasis progression using LC-MS/MS-based targeted metabolomics and lipidomics. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s13058-018-1075-yDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6278167PMC
December 2018
2 Reads

Risk prediction for estrogen receptor-specific breast cancers in two large prospective cohorts.

Breast Cancer Res 2018 12 3;20(1):147. Epub 2018 Dec 3.

Nutritional Methodology and Biostatistics Group, Nutrition and Metabolism Section, International Agency for Research on Cancer, 150 cours Albert Thomas, 69372, Lyon Cedex 08, France.

Background: Few published breast cancer (BC) risk prediction models consider the heterogeneity of predictor variables between estrogen-receptor positive (ER+) and negative (ER-) tumors. Using data from two large cohorts, we examined whether modeling this heterogeneity could improve prediction.

Methods: We built two models, for ER+ (Model) and ER- tumors (Model), respectively, in 281,330 women (51% postmenopausal at recruitment) from the European Prospective Investigation into Cancer and Nutrition cohort. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s13058-018-1073-0DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6276150PMC
December 2018
5 Reads

Induction of cell cycle arrest and inflammatory genes by combined treatment with epigenetic, differentiating, and chemotherapeutic agents in triple-negative breast cancer.

Breast Cancer Res 2018 11 28;20(1):145. Epub 2018 Nov 28.

Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.

Background: A combination of entinostat, all-trans retinoic acid, and doxorubicin (EAD) induces cell death and differentiation and causes significant regression of xenografts of triple-negative breast cancer (TNBC).

Methods: We investigated the mechanisms underlying the antitumor effects of each component of the EAD combination therapy by high-throughput gene expression profiling of drug-treated cells.

Results: Microarray analysis showed that entinostat and doxorubicin (ED) altered expression of genes related to growth arrest, inflammation, and differentiation. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s13058-018-1068-xDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6263070PMC
November 2018
3 Reads

Associations between self-reported diet during treatment and chemotherapy-induced peripheral neuropathy in a cooperative group trial (S0221).

Breast Cancer Res 2018 11 28;20(1):146. Epub 2018 Nov 28.

Roswell Park Cancer Institute, Buffalo, NY, USA.

Background: The pathophysiology of chemotherapy-induced peripheral neuropathy (CIPN) is not well understood. Currently, dose reduction is the only recommendation for alleviating symptoms, often leading to premature treatment cessation. The primary aim of this analysis was to determine the association between components of diet during taxane treatment for breast cancer and change in CIPN symptoms over treatment. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s13058-018-1077-9DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6264595PMC
November 2018
6 Reads

Insulin-like growth factor receptor signaling in breast tumor epithelium protects cells from endoplasmic reticulum stress and regulates the tumor microenvironment.

Breast Cancer Res 2018 11 20;20(1):138. Epub 2018 Nov 20.

Department of Pharmacology, Physiology & Neuroscience, Rutgers-New Jersey Medical School, Cancer Institute of New Jersey, Newark, NJ, 07101, USA.

Background: Early analyses of human breast cancer identified high expression of the insulin-like growth factor type 1 receptor (IGF-1R) correlated with hormone receptor positive breast cancer and associated with a favorable prognosis, whereas low expression of IGF-1R correlated with triple negative breast cancer (TNBC). We previously demonstrated that the IGF-1R acts as a tumor and metastasis suppressor in the Wnt1 mouse model of TNBC. The mechanisms for how reduced IGF-1R contributes to TNBC phenotypes is unknown. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s13058-018-1063-2DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6245538PMC
November 2018
9 Reads

HER4 expression in estrogen receptor-positive breast cancer is associated with decreased sensitivity to tamoxifen treatment and reduced overall survival of postmenopausal women.

Breast Cancer Res 2018 11 20;20(1):139. Epub 2018 Nov 20.

Clinic of Gynecology and Obstetrics, University Medical Center Regensburg, Regensburg, Germany.

Background: The sensitivity of estrogen receptor-positive breast cancers to tamoxifen treatment varies considerably, and the molecular mechanisms affecting the response rates are manifold. The human epidermal growth factor receptor-related receptor HER2 is known to trigger intracellular signaling cascades that modulate the activity of coregulators of the estrogen receptor which, in turn, reduces the cell sensitivity to tamoxifen treatment. However, the impact of HER2-related receptor tyrosine kinases HER1, HER3, and, in particular, HER4 on endocrine treatment is largely unknown. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s13058-018-1072-1DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6247692PMC
November 2018
11 Reads

Denosumab treatment is associated with the absence of circulating tumor cells in patients with breast cancer.

Breast Cancer Res 2018 11 20;20(1):141. Epub 2018 Nov 20.

Department of Biomedicine, Cancer Metastasis Laboratory, University of Basel and University Hospital Basel, Mattenstrasse 28, CH-4058, Basel, Switzerland.

Background: The presence of circulating tumor cells (CTCs) in patients with breast cancer correlates to a bad prognosis. Yet, CTCs are detectable in only a minority of patients with progressive breast cancer, and factors that influence the abundance of CTCs remain elusive.

Methods: We conducted CTC isolation and enumeration in a selected group of 73 consecutive patients characterized by progressive invasive breast cancer, high tumor load and treatment discontinuation at the time of CTC isolation. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s13058-018-1067-yDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6247738PMC
November 2018
15 Reads

No association between low-dose aspirin use and breast cancer outcomes overall: a Swedish population-based study.

Breast Cancer Res 2018 11 20;20(1):142. Epub 2018 Nov 20.

Department of Medicine Solna, Division of Clinical Epidemiology, Karolinska Institutet and Karolinska University Hospital, SE-171 76, Stockholm, Sweden.

Background: Results from previous studies indicate that use of low-dose aspirin may improve breast cancer prognosis. We evaluated aspirin use and breast cancer outcomes in relation to clinical characteristics as well as dose and duration of aspirin use.

Methods: We used information from the Regional Breast Cancer Quality-of-Care Registries in three Swedish regions to identify 21,414 women diagnosed with a first stage I-III breast cancer between 1 April 2006 and 31 December 2012. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s13058-018-1065-0DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6247765PMC
November 2018
7 Reads

Molecular patterns of cancer colonisation in lymph nodes of breast cancer patients.

Breast Cancer Res 2018 11 20;20(1):143. Epub 2018 Nov 20.

Cancer Bioinformatics, King's College London, Innovation Hub, Cancer Centre at Guy's Hospital, Great Maze Pond, London, SE1 9RT, UK.

Lymph node (LN) metastasis is an important prognostic parameter in breast carcinoma, a crucial site for tumour-immune cell interaction and a gateway for further dissemination of tumour cells to other metastatic sites. To gain insight into the underlying molecular changes from the pre-metastatic, via initial colonisation to the fully involved LN, we reviewed transcriptional research along the evolving microenvironment of LNs in human breast cancers patients. Gene expression studies were compiled and subjected to pathway-based analyses, with an emphasis on immune cell-related genes. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s13058-018-1070-3DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6247766PMC
November 2018
9 Reads

Cleavage of the extracellular domain of junctional adhesion molecule-A is associated with resistance to anti-HER2 therapies in breast cancer settings.

Breast Cancer Res 2018 11 20;20(1):140. Epub 2018 Nov 20.

Department of Surgery, Royal College of Surgeons in Ireland, RCSI Education and Research Centre, Beaumont Hospital, Dublin 9, Ireland.

Background: Junctional adhesion molecule-A (JAM-A) is an adhesion molecule whose overexpression on breast tumor tissue has been associated with aggressive cancer phenotypes, including human epidermal growth factor receptor-2 (HER2)-positive disease. Since JAM-A has been described to regulate HER2 expression in breast cancer cells, we hypothesized that JAM-dependent stabilization of HER2 could participate in resistance to HER2-targeted therapies.

Methods: Using breast cancer cell line models resistant to anti-HER2 drugs, we investigated JAM-A expression and the effect of JAM-A silencing on biochemical/functional parameters. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s13058-018-1064-1DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6247757PMC
November 2018
4 Reads

Statin drugs to reduce breast cancer recurrence and mortality.

Breast Cancer Res 2018 11 20;20(1):144. Epub 2018 Nov 20.

Department of Pathology, University of Pittsburgh, Pittsburgh, 15231, PA, USA.

Epidemiologic studies have, variably, shown the concomitant use of statin drugs to be beneficial to cancer outcomes. Statin drugs have been FDA approved for three decades for the treatment of high cholesterol and atherosclerotic coronary artery disease and are widely used. This has engendered studies as to their influence on concomitant diseases, including cancers. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s13058-018-1066-zDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6247616PMC
November 2018
13 Reads

Correction to: Consistent and reproducible cultures of large-scale 3D mammary epithelial structures using an accessible bioprinting platform.

Breast Cancer Res 2018 11 19;20(1):136. Epub 2018 Nov 19.

School of Medical Diagnostic & Translational Sciences, College of Health Sciences, Old Dominion University, 5115 Hampton Blvd, Norfolk, VA, 23529, USA.

Following publication of the original article [1], the authors reported a typesetting error in the spelling of the second author's name. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s13058-018-1069-9DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6245868PMC
November 2018
1 Read

Sortilin inhibition limits secretion-induced progranulin-dependent breast cancer progression and cancer stem cell expansion.

Breast Cancer Res 2018 11 20;20(1):137. Epub 2018 Nov 20.

Department of Pathology and Genetics, Institute of Biomedicine, Sahlgrenska Cancer Center, University of Gothenburg, Gothenburg, Sweden.

Background: Cancer progression is influenced by genetic aberrations in the cancer cell population as well as by other factors including the microenvironment present within a tumour. Direct interactions between various cell types as well as cellular signalling via secreted cytokines can drive key tumourigenic properties associated with disease progression and treatment resistance. Also, cancer stem cell functions are influenced by the microenvironment. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s13058-018-1060-5DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6245804PMC
November 2018
4 Reads

Inflammation markers and cognitive performance in breast cancer survivors 20 years after completion of chemotherapy: a cohort study.

Breast Cancer Res 2018 11 15;20(1):135. Epub 2018 Nov 15.

Department of Psychosocial Research and Epidemiology, Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX, Amsterdam, the Netherlands.

Background: Inflammation is an important candidate mechanism underlying cancer and cancer treatment-related cognitive impairment. We investigated levels of blood cell-based inflammatory markers in breast cancer survivors on average 20 years after chemotherapy and explored the relation between these markers and global cognitive performance.

Methods: One hundred sixty-six breast cancer survivors who received post-surgical radiotherapy and six cycles of adjuvant cyclophosphamide, methotrexate, and fluorouracil (CMF) chemotherapy on average 20 years before enrollment were compared with 1344 cancer-free women from a population-based sample (50-80 years old). Read More

View Article

Download full-text PDF

Source
https://breast-cancer-research.biomedcentral.com/articles/10
Publisher Site
http://dx.doi.org/10.1186/s13058-018-1062-3DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6238315PMC
November 2018
5 Reads

Evaluation of osteopenia and osteoporosis in younger breast cancer survivors compared with cancer-free women: a prospective cohort study.

Breast Cancer Res 2018 11 13;20(1):134. Epub 2018 Nov 13.

Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, 21205, USA.

Background: Osteoporosis, an indicator of significant bone loss, has been consistently reported among older breast cancer survivors. Data are limited on the incidence of osteopenia, an earlier indicator of bone loss, and osteoporosis in younger breast cancer survivors compared with cancer-free women.

Methods: We prospectively examined bone loss in 211 breast cancer survivors (mean age at breast cancer diagnosis = 47 years) compared with 567 cancer-free women in the same cohort with familial risk for breast cancer. Read More

View Article

Download full-text PDF

Source
https://breast-cancer-research.biomedcentral.com/articles/10
Publisher Site
http://dx.doi.org/10.1186/s13058-018-1061-4DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6234595PMC
November 2018
14 Reads

Sulfatide decreases the resistance to stress-induced apoptosis and increases P-selectin-mediated adhesion: a two-edged sword in breast cancer progression.

Breast Cancer Res 2018 11 6;20(1):133. Epub 2018 Nov 6.

Department of Biochemistry and Molecular Biology, Faculty of Veterinary Medicine, Wroclaw University of Environmental and Life Sciences, C.K. Norwida 31, 50-375, Wroclaw, Poland.

Background: We have previously shown that galactosylceramide (GalCer) affects the tumourigenic and metastatic properties of breast cancer cells by acting as an anti-apoptotic molecule. Since GalCer is a precursor molecule in the synthesis of sulfatides, the present study was aimed to define the role of sulfatides in apoptosis and breast cancer progression.

Methods: Expression of GAL3ST1 in breast cancer cell lines and breast cancer tissue specimens was analysed using real-time PCR, western blotting and immunohistochemistry analysis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s13058-018-1058-zDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6219063PMC
November 2018
2 Reads

Age-specific breast cancer risk by body mass index and familial risk: prospective family study cohort (ProF-SC).

Breast Cancer Res 2018 11 3;20(1):132. Epub 2018 Nov 3.

Department of Epidemiology, Mailman School of Public Health, Columbia University, 722 W 168th St, 7th Floor, New York, NY, USA.

Background: The association between body mass index (BMI) and risk of breast cancer depends on time of life, but it is unknown whether this association depends on a woman's familial risk.

Methods: We conducted a prospective study of a cohort enriched for familial risk consisting of 16,035 women from 6701 families in the Breast Cancer Family Registry and the Kathleen Cunningham Foundation Consortium for Research into Familial Breast Cancer followed for up to 20 years (mean 10.5 years). Read More

View Article

Download full-text PDF

Source
https://breast-cancer-research.biomedcentral.com/articles/10
Publisher Site
http://dx.doi.org/10.1186/s13058-018-1056-1DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6215632PMC
November 2018
14 Reads